Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Nitric oxide (NO) is a ubiquitous signaling molecule with complex, context-dependent roles in human physiology. Dysregulated NO production contributes to the progression of various diseases, notably affecting women’s health in areas such as pregnancy, autoimmune disorders, cardiovascular conditions, endometriosis, chronic pain, and postmenopausal complications. Despite its therapeutic potential, drug development targeting the NO pathway remains challenging due to its pleiotropic effects and systemic nature.
Our research focuses on harnessing the therapeutic potential of NO through precise and controlled modulation. We are developing stimuli-responsive NO donors and novel peptides that selectively inhibit inducible nitric oxide synthase (iNOS) in a targeted manner. This approach aims to deliver tissue-specific therapeutic effects, minimizing systemic side effects and addressing the limitations of current NO-modulating therapies.
